eClinical

In this Q&A, leaders from Bioforum, KCR, Syneos Health, and Veeva come together to share insights on the state of digital clinical trials and how the industry will evolve over the next couple of years.

EU Medical Device Regulation must be followed carefully as it leaves room for interpretation.

Melissa Easy, VP and GM, clinical technologies at IQVIA speaks about concerns with clinical technology at the SCOPE 2023 conference in Orlando, FL.

How evidence generated by the latest IgniteData ‘real-setting’ pilot study supports the case for clinical trial transformation.

Sam Whitaker, co-founder and co-CEO of Mural Health discusses his time in the industry and patient needs in the current clinical trials market.

Providing patients with more flexibility in how they choose to participate in trials.

Good scientific principles and practices are essential for maintaining quality data that patients can benefit from.

Survey results emphasize need for flexibility in strategies.

Lindsay Hughes, PhD, principal scientific advisor of Clario discusses the current eCOA environment, new technology applications, and how technology implementations should be supported by science.

The many different shapes and sizes of vendors requires a thoughtful process for selection.

All stakeholders must play part in increasing implementation.

While eConsent has become more widely adopted since COVID-19, work still needs to be done in improving patients’ understanding.

Moving past the ‘if’ to the ‘how.’

COVID has accelerated to the scene upstart digital efforts to transform patient engagement and data management/integration—but progress remains measured.

Consortium looks to advance endpoint assessment through the development of eCOA best practices.

Understanding differences in studies, sites, and patients are key to making eConsent successful.

Breaking down the barriers to eConsent adoption.

Finalizing protocols, aligning teams, and staying engaged headline best practices.

Six best practices and three key mistakes to avoid in new technology space.

Phase I/II study in cancer patients showcases eClinical effectiveness.

New requirements must be put in place to ensure data quality and integrity.

How site management team leader Emma Earl, a 2021 Veeva R&D Hero, is developing a culture of improvement at Bayer, or what Japanese business strategists have long called Kaizen, in its clinical operations.

eTMF-blockchain technology offers a myriad of application benefits to data quality and integrity while ensuring compliance to ethical standards.